Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.51 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13961958 | 0.98 | PSMB8 (0.53) | PSMB8PSMB9PSMB5PDE2AKMO | |
| SCHEMBL11900265 | 0.84 | PSMB8 (0.49) | PSMB8PSMB9PSMB5PDE2AKMO | |
| SCHEMBL3941812 | 0.83 | PSMB8 (0.51) | PSMB8PSMB9PSMB5PDE2AKMO | |
| SCHEMBL30489440 | 0.81 | PSMB8 (0.50) | PSMB8PSMB9PSMB5PDE2AKMO | |
| SCHEMBL21317604 | 0.81 | PSMB8 (0.50) | PSMB8PSMB9PSMB5PDE2AKMO | |
| SCHEMBL21317603 | 0.81 | PSMB8 (0.53) | PSMB8PSMB9PSMB5PDE2AKMO | |
| SCHEMBL18811687 | 0.81 | PSMB8 (0.53) | PSMB8PSMB9PSMB5PDE2AKMO | |
| SCHEMBL18811689 | 0.81 | PSMB8 (0.53) | PSMB8PSMB9PSMB5PDE2AKMO | |
| SCHEMBL20781328 | 0.81 | HCAR2 (0.47) | PSMB8PSMB9PSMB5PDE2AKMO | |
| SCHEMBL23930529 | 0.79 | PSMB8 (0.48) | PSMB8PSMB9PSMB5PDE2AKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697979-B | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4139287-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| EP-4139287-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115697979-A | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021214020-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | PSMB8 2758/4885PSMB9 1723/4885PSMB5 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.